FarFaR - Pharmacy Repository
University of Belgrade, Faculty of Pharmacy
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrillic)
    • Serbian (Latin)
  • Login
View Item 
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Factorial analysis of N-acetylcysteine and propolis treatment effects on symptoms, life quality and exacerbations in patients with Chronic Obstructive Pulmonary Disease (COPD): a randomized, double-blind, placebo-controlled trial

Thumbnail
2022
Factorial_analysis_of_pub_2022.pdf (387.8Kb)
Authors
Kolarov, V.
Kotur-Stevuljević, Jelena
Ilić, M.
Bogdan, M.
Tušek, B.
Agic, A.
Dugajlić, M.
Tot Vereš, K.
Kutlešić Stević, S.
Zvezdin, B.
Article (Published version)
Metadata
Show full item record
Abstract
OBJECTIVE: Standard treatment for chronic obstructive pulmonary disease (COPD) includes inhalation therapy along with mucoactive drugs. The aim of this study was to assess the efficacy and safety of orally administered mucolytic N-acetylcysteine and propolis (NACp) in COPD patients. PATIENTS AND METHODS: A randomized, double-blind, prospective, interventional, 6 months study was conducted at the Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia. Effects of daily NACp administration (600 mg, 1200 mg or placebo) on exacerbation, life quality (St. George's Respiratory Questionnaire-SGRQ), symptoms (COPD assessment test-CAT; Visual analogue cough scale-VAS; Leicester Cough Questionnaire-LCQ; Medical Research Council Dyspnoea scale-mMRC) and spirometric parameters in 120 COPD patients were assessed. Tests were conducted at three-time points: baseline, after three months and after 6 months of NACp treatment. RESULTS: Repeated measures ANOVA showed that pulmonary functio...n parameters, 6-minute walk test and mMRC score did not significantly change during the study. Cough VAS and CAT scores were significantly different between groups as within experimental groups. LCQ and SGRQ scores did not differ between placebo, and both examined groups, but within each examined group statistically significant difference was confirmed in observed parameters during therapy. Factorial analysis and subsequent binary logistic regression revealed "Symptoms related factor" as the strongest predictor of exacerbation for supplemented groups (p<0.01). CONCLUSIONS: Treatment with high NACp for 6 months is safe and beneficial for cough and expectoration symptoms and improves the life quality. NACp significantly reduces acute exacerbation frequency in COPD patients by controlling COPD related symptoms.

Keywords:
COPD / NAC / Propolis / Exacerbation / Cough / Life quality
Source:
European Review for Medical and Pharmacological Sciences, 2022, 26, 9, 3192-3199
Publisher:
  • Verduci Editore srl

DOI: 10.26355/eurrev_202205_28737

ISSN: 1128-3602

WoS: 00083294640001

Scopus: 2-s2.0-85130249551
[ Google Scholar ]
4
URI
https://farfar.pharmacy.bg.ac.rs/handle/123456789/4176
Collections
  • Radovi istraživača / Researchers’ publications
Institution/Community
Pharmacy
TY  - JOUR
AU  - Kolarov, V.
AU  - Kotur-Stevuljević, Jelena
AU  - Ilić, M.
AU  - Bogdan, M.
AU  - Tušek, B.
AU  - Agic, A.
AU  - Dugajlić, M.
AU  - Tot Vereš, K.
AU  - Kutlešić Stević, S.
AU  - Zvezdin, B.
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4176
AB  - OBJECTIVE: Standard treatment for chronic obstructive pulmonary disease (COPD) includes inhalation therapy along with mucoactive drugs. The aim of this study was to assess the efficacy and safety of orally administered mucolytic N-acetylcysteine and propolis (NACp) in COPD patients. PATIENTS AND METHODS: A randomized, double-blind, prospective, interventional, 6 months study was conducted at the Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia. Effects of daily NACp administration (600 mg, 1200 mg or placebo) on exacerbation, life quality (St. George's Respiratory Questionnaire-SGRQ), symptoms (COPD assessment test-CAT; Visual analogue cough scale-VAS; Leicester Cough Questionnaire-LCQ; Medical Research Council Dyspnoea scale-mMRC) and spirometric parameters in 120 COPD patients were assessed. Tests were conducted at three-time points: baseline, after three months and after 6 months of NACp treatment. RESULTS: Repeated measures ANOVA showed that pulmonary function parameters, 6-minute walk test and mMRC score did not significantly change during the study. Cough VAS and CAT scores were significantly different between groups as within experimental groups. LCQ and SGRQ scores did not differ between placebo, and both examined groups, but within each examined group statistically significant difference was confirmed in observed parameters during therapy. Factorial analysis and subsequent binary logistic regression revealed "Symptoms related factor" as the strongest predictor of exacerbation for supplemented groups (p<0.01). CONCLUSIONS: Treatment with high NACp for 6 months is safe and beneficial for cough and expectoration symptoms and improves the life quality. NACp significantly reduces acute exacerbation frequency in COPD patients by controlling COPD related symptoms.
PB  - Verduci Editore srl
T2  - European Review for Medical and Pharmacological Sciences
T1  - Factorial analysis of N-acetylcysteine and propolis treatment effects on symptoms, life quality and exacerbations in patients with Chronic Obstructive Pulmonary Disease (COPD): a randomized, double-blind, placebo-controlled trial
VL  - 26
IS  - 9
SP  - 3192
EP  - 3199
DO  - 10.26355/eurrev_202205_28737
ER  - 
@article{
author = "Kolarov, V. and Kotur-Stevuljević, Jelena and Ilić, M. and Bogdan, M. and Tušek, B. and Agic, A. and Dugajlić, M. and Tot Vereš, K. and Kutlešić Stević, S. and Zvezdin, B.",
year = "2022",
abstract = "OBJECTIVE: Standard treatment for chronic obstructive pulmonary disease (COPD) includes inhalation therapy along with mucoactive drugs. The aim of this study was to assess the efficacy and safety of orally administered mucolytic N-acetylcysteine and propolis (NACp) in COPD patients. PATIENTS AND METHODS: A randomized, double-blind, prospective, interventional, 6 months study was conducted at the Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia. Effects of daily NACp administration (600 mg, 1200 mg or placebo) on exacerbation, life quality (St. George's Respiratory Questionnaire-SGRQ), symptoms (COPD assessment test-CAT; Visual analogue cough scale-VAS; Leicester Cough Questionnaire-LCQ; Medical Research Council Dyspnoea scale-mMRC) and spirometric parameters in 120 COPD patients were assessed. Tests were conducted at three-time points: baseline, after three months and after 6 months of NACp treatment. RESULTS: Repeated measures ANOVA showed that pulmonary function parameters, 6-minute walk test and mMRC score did not significantly change during the study. Cough VAS and CAT scores were significantly different between groups as within experimental groups. LCQ and SGRQ scores did not differ between placebo, and both examined groups, but within each examined group statistically significant difference was confirmed in observed parameters during therapy. Factorial analysis and subsequent binary logistic regression revealed "Symptoms related factor" as the strongest predictor of exacerbation for supplemented groups (p<0.01). CONCLUSIONS: Treatment with high NACp for 6 months is safe and beneficial for cough and expectoration symptoms and improves the life quality. NACp significantly reduces acute exacerbation frequency in COPD patients by controlling COPD related symptoms.",
publisher = "Verduci Editore srl",
journal = "European Review for Medical and Pharmacological Sciences",
title = "Factorial analysis of N-acetylcysteine and propolis treatment effects on symptoms, life quality and exacerbations in patients with Chronic Obstructive Pulmonary Disease (COPD): a randomized, double-blind, placebo-controlled trial",
volume = "26",
number = "9",
pages = "3192-3199",
doi = "10.26355/eurrev_202205_28737"
}
Kolarov, V., Kotur-Stevuljević, J., Ilić, M., Bogdan, M., Tušek, B., Agic, A., Dugajlić, M., Tot Vereš, K., Kutlešić Stević, S.,& Zvezdin, B.. (2022). Factorial analysis of N-acetylcysteine and propolis treatment effects on symptoms, life quality and exacerbations in patients with Chronic Obstructive Pulmonary Disease (COPD): a randomized, double-blind, placebo-controlled trial. in European Review for Medical and Pharmacological Sciences
Verduci Editore srl., 26(9), 3192-3199.
https://doi.org/10.26355/eurrev_202205_28737
Kolarov V, Kotur-Stevuljević J, Ilić M, Bogdan M, Tušek B, Agic A, Dugajlić M, Tot Vereš K, Kutlešić Stević S, Zvezdin B. Factorial analysis of N-acetylcysteine and propolis treatment effects on symptoms, life quality and exacerbations in patients with Chronic Obstructive Pulmonary Disease (COPD): a randomized, double-blind, placebo-controlled trial. in European Review for Medical and Pharmacological Sciences. 2022;26(9):3192-3199.
doi:10.26355/eurrev_202205_28737 .
Kolarov, V., Kotur-Stevuljević, Jelena, Ilić, M., Bogdan, M., Tušek, B., Agic, A., Dugajlić, M., Tot Vereš, K., Kutlešić Stević, S., Zvezdin, B., "Factorial analysis of N-acetylcysteine and propolis treatment effects on symptoms, life quality and exacerbations in patients with Chronic Obstructive Pulmonary Disease (COPD): a randomized, double-blind, placebo-controlled trial" in European Review for Medical and Pharmacological Sciences, 26, no. 9 (2022):3192-3199,
https://doi.org/10.26355/eurrev_202205_28737 . .

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceCommunitiesAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB